drugset / Trial / NCT05309213
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NaSequentialOpen-labelTreatment
Summary
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
Timeline
- Start
- 2022-04-01
- Primary completion
- 2025-04-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IM19 CAR-T cells | Cell therapy | 50000 cells/kg | — |
| Subject | IM19 CAR-T cells | Cell therapy | 100000 cells/kg | — |
| Subject | IM19 CAR-T cells | Cell therapy | 300000 cells/kg | — |
| Subject | IM19 CAR-T cells | Cell therapy | 1e+06 cells/kg | — |